Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicentre, Single-arm, Open-label Study to Evaluate the Long-term Safety of Z-338 in Subjects With Functional Dyspepsia

Trial Profile

A Phase III, Multicentre, Single-arm, Open-label Study to Evaluate the Long-term Safety of Z-338 in Subjects With Functional Dyspepsia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acotiamide (Primary)
  • Indications Non-ulcer dyspepsia
  • Focus Adverse reactions; Registrational
  • Sponsors Zeria
  • Most Recent Events

    • 05 Jun 2018 Results assessing long-term safety and efficacy of acotiamide treatment were presented at the Digestive Disease Week 2018.
    • 27 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 26 Mar 2017 This trial has been completed in the United Kingdom (end date: 30 Sep 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top